Kite Pharma Reports Second Quarter 2016 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. HNGE
9. INSP
10. SPY

Go back to Kite Pharma Reports Second Quarter 2016 Financial Results

Kite Pharma (KITE) PT Trimmed to $77 at Maxim Group

August 9, 2016 7:56 AM EDT

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Kite Pharma (NASDAQ: KITE) but lowered its price target to $77.00 (from $87.00) following Q2 results.

McCarthy highlighted:

Kite reported 2Q16 with $4.8M in revenue and a net loss of $64.3M. The company began the quarter with $531M in cash.Kite continues to advance its lead CAR-T program KTE-C19 towards pivotal data, expected this fall. The ZUMA-1 study has completed enrollment of all 72 relapsed/refractory (r/r, i.e. salvage setting) lymphoma patients and data from the first 50 patients,... More